BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 35380720)

  • 1. Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma.
    Lin C; Lin K; Zhang B; Su Y; Guo Q; Lu T; Xu Y; Lin S; Zong J; Pan J
    Oncologist; 2022 Apr; 27(4):e340-e349. PubMed ID: 35380720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Epstein-Barr virus microRNA BART8-3p as a potential biomarker for detection and prognostic prediction in early nasopharyngeal carcinoma.
    Lin C; Chen Y; Lin X; Peng H; Huang J; Lin S; Pan J; Li M; Zong J
    Sci Rep; 2024 Mar; 14(1):7433. PubMed ID: 38548853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-κB and Erk1/2 pathways.
    Lin C; Zong J; Lin W; Wang M; Xu Y; Zhou R; Lin S; Guo Q; Chen H; Ye Y; Zhang B; Pan J
    J Exp Clin Cancer Res; 2018 Nov; 37(1):283. PubMed ID: 30477559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.
    Lu T; Guo Q; Lin K; Chen H; Chen Y; Xu Y; Lin C; Su Y; Chen Y; Chen M; Zheng Y; Ye Y; Lin S; Zong J; Pan J
    Cancer Sci; 2020 May; 111(5):1711-1723. PubMed ID: 32155300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus (EBV) encoded microRNA BART8-3p drives radioresistance-associated metastasis in nasopharyngeal carcinoma.
    Zhou X; Lin Y; Chen Y; Wang L; Peng X; Liao J; Zeng H; Luo W; Wu D; Cai L
    J Cell Physiol; 2021 Sep; 236(9):6457-6471. PubMed ID: 33694159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of Epstein-Barr virus (EBV)-encoded microRNAs in plasma of patients with nasopharyngeal carcinoma.
    Gao W; Wong TS; Lv KX; Zhang MJ; Tsang RK; Chan JY
    Head Neck; 2019 Mar; 41(3):780-792. PubMed ID: 30548946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EBV encoded miRNA BART8-3p promotes radioresistance in nasopharyngeal carcinoma by regulating ATM/ATR signaling pathway.
    Zhou X; Zheng J; Tang Y; Lin Y; Wang L; Li Y; Liu C; Wu D; Cai L
    Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31471531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
    Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
    Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.
    Chen WH; Tang LQ; Guo SS; Chen QY; Zhang L; Liu LT; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
    Medicine (Baltimore); 2016 Feb; 95(5):e2642. PubMed ID: 26844482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vesicle-bound EBV-BART13-3p miRNA in circulation distinguishes nasopharyngeal from other head and neck cancer and asymptomatic EBV-infections.
    Ramayanti O; Verkuijlen SAWM; Novianti P; Scheepbouwer C; Misovic B; Koppers-Lalic D; van Weering J; Beckers L; Adham M; Martorelli D; Middeldorp JM; Pegtel DM
    Int J Cancer; 2019 May; 144(10):2555-2566. PubMed ID: 30411781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
    Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
    Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic effect of residual plasma Epstein-Barr viral DNA after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Zheng H; Zhou P; Wang J; Yu YF; Zhou R; Lin Q; Wu SG
    Cancer Med; 2023 Jul; 12(14):14979-14987. PubMed ID: 37212447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
    Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of miR-3182 and EBV-miR-BART8-3p in nasopharyngeal carcinoma is correlated with distant metastasis.
    Mo X; Yin W; Huang Y; Guo W; Zhou M; Ye H
    Int J Clin Exp Pathol; 2018; 11(6):3134-3140. PubMed ID: 31938442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
    Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
    Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.
    Li W; Chen J; Liang B; Li Z; Li J; Yuan X; Wu S; Zeng F; Peng X; Li Y; Lu J; Zhao F; Liu X
    Cancer Med; 2021 Feb; 10(3):883-894. PubMed ID: 33378109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
    Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY
    Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.
    Zhang G; Zong J; Lin S; Verhoeven RJ; Tong S; Chen Y; Ji M; Cheng W; Tsao SW; Lung M; Pan J; Chen H
    Int J Cancer; 2015 Mar; 136(5):E301-12. PubMed ID: 25213622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma.
    Lung RW; Hau PM; Yu KH; Yip KY; Tong JH; Chak WP; Chan AW; Lam KH; Lo AK; Tin EK; Chau SL; Pang JC; Kwan JS; Busson P; Young LS; Yap LF; Tsao SW; To KF; Lo KW
    J Pathol; 2018 Apr; 244(4):394-407. PubMed ID: 29230817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma.
    Wang G; Dong Z; Huang C; Du X; Chen L; Li K; Guo R; Tang L; Ma J
    Oral Oncol; 2023 Oct; 145():106500. PubMed ID: 37467683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.